Overview: Anti-Mitochondrial Antibody Dilutions TestIntroduction: The Anti-Mitochondrial Antibody Dilutions Test detects AMA in dilutions to diagnose primary biliary cholangitis, causing liver dysfunction. Aligned with 2023 AASLD guidelines, it uses immunofluorescence assay for high specificity, supporting liver screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in immunology for patients with suspected PBC, particularly in complex cases.
Other Names: AMA Dilution Assay, PBC Dilution Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: AMA dilution testing began in the 1970s with autoimmune liver research. Immunofluorescence methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects AMA in dilutions to diagnose primary biliary cholangitis, guides treatment, and evaluates patients with liver dysfunction.
Test Parameters: 1. Mitochondrial Antibodies (Dilutions)
Pretest Condition: No fasting required. Collect serum or saliva. Report history of liver dysfunction, jaundice, or fatigue.
Specimen: Serum (SST, 2-5 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document liver dysfunction, jaundice, itching, or family history of autoimmune liver diseases. Include current medications, especially ursodiol.
Consent: Written consent required, detailing the tests purpose, PBC implications, and risks of sample collection.
Procedural Considerations: Uses immunofluorescence assay with dilution to detect AMA in serum or saliva. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for complex PBC diagnosis.
Factors Affecting Result Accuracy: Hemolysis, lipemia, or improper sample storage can affect results. Insufficient sample volume may reduce accuracy.
Clinical Significance: Positive AMA in dilutions confirms PBC, guiding treatment (e.g., ursodiol). Negative results may require further liver testing.
Specialist Consultation: Consult a hepatologist for result interpretation and treatment planning.
Additional Supporting Tests: Liver function tests, ANA, or liver biopsy to confirm PBC diagnosis.
Test Limitations: Dilution increases specificity but may reduce sensitivity; clinical correlation is needed.
References: AASLD PBC Guidelines, 2023; Hepatology, Lindor KD, 2022.
